In this review, we describe several critical clinical trials in recent years that have set the landscape for emerging ischemic stroke therapies in the era of late time point reperfusion, and we reflect upon these lessons within the context of our own work in targeting the voltage-gated potassium channel Kv2.1 for neuroprotection. Here, KCNB1 is linked to ischemic stroke.